Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.7%

1 terminated/withdrawn out of 37 trials

Success Rate

95.8%

+9.3% vs industry average

Late-Stage Pipeline

32%

12 trials in Phase 3/4

Results Transparency

13%

3 of 23 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4
12(54.5%)
N/A
6(27.3%)
Phase 2
4(18.2%)
22Total
Phase 4(12)
N/A(6)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials
NCT04181567Phase 4Completed

Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients

Role: collaborator

NCT01390376Phase 2Completed

DAAOI-1 Treatment for Treatment-resistant Schizophrenia

Role: collaborator

NCT02704962Phase 4Completed

Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine

Role: collaborator

NCT02194686Phase 4Completed

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease

Role: collaborator

NCT02174939Phase 4Unknown

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease

Role: collaborator

NCT01549275Completed

Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration

Role: collaborator

NCT00979979Completed

Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test

Role: collaborator

NCT01952756Phase 4Completed

Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)

Role: collaborator

NCT00532701Phase 4Completed

Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR

Role: collaborator

NCT01930656Completed

Mobile Device to Help FRAX® Screening

Role: collaborator

NCT00491244Phase 4Completed

Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

Role: collaborator

NCT01972958Not ApplicableCompleted

Effects of Community Health Programs by Nurses for Older Adults

Role: collaborator

NCT00728546Phase 4Unknown

NAT2 in Re-challenge of INH in Patients With Hepatitis

Role: collaborator

NCT00251017Not ApplicableCompleted

Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs

Role: collaborator

NCT00977054Phase 4Terminated

Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load

Role: collaborator

NCT00713362Phase 2Unknown

Chest Tube Drainage or Thoracoscopic Surgery for Failed Aspiration of Spontaneous Pneumothorax

Role: collaborator

NCT01738061Not ApplicableCompleted

A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan

Role: collaborator

NCT01503645Unknown

Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism

Role: collaborator

NCT01359501Phase 2Unknown

Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients

Role: collaborator

NCT01138878Completed

HIV Testing in Non-traditional Settings Study

Role: collaborator